As Economist Impact’s World Cancer Series continues, Day Two firmly takes up focus on the patient voice, with a presentation by Eileen Page, chief executive of Innovation Advantage 2020 to
CEO/President Matt D’Auria Headquarters
In July, when the FDA approved Eisai and Biogen’s Alzheimer’s drug Leqembi, we noted the historic natu
Cancer Research UK (CRUK) has said it will award £123 million ($150 million) in funding over the next seven years to Scotland’s Beatson Institute, which will be renamed th
Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the
Views & Analysis
White Papers & Webinar
Podcasts & Video
(Berlin, Germany and Salerno, Italy) - On September 18th, 2023, Allis.Health, a new digital health analyst platform, offi
WASHINGTON, D.C., Sept.
The 2nd Innate Killer Europe Summit will gather 80+ key European Gamma Delta T, NK, iNKT, neutrophil, and macrophage developers in October to chase the holy grail of efficacious, off-the-sh
The 3rd Synthetic Biology-Based Therapeutics Summit is a platform uniting academia, engineers, and drug developers working towards increased specificity, durability and potency.